Piper Sandler raised the firm’s price target on Cytek Biosciences (CTKB) to $8.50 from $8 following quarterly results. The firm keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTKB:
- Cytek Biosciences introduces ESP Detection Option for Cytek Aurora
- Trump Media, broader market surge after Trump wins election: Morning Buzz
- Cytek Biosciences’ Q3 2024 Financial Highlights
- Cytek Biosciences reports Q3 EPS 1c, consensus (2c)
- CTKB Earnings Report this Week: Is It a Buy, Ahead of Earnings?